| | Year 1 |
Years 1–5 | Patient subpopulation (determined at index date) | Alzheimer cohort n = 37,138 Mean (SD) | Comparison cohort n = 37,138 | value | Alzheimer cohort n = 37,138 | Comparison cohort n = 37,138 | value |
| History of cerebrovascular accident | | | | | | | Yes | 10,616 (13,140) | 8,242 (12,301) | <.001 | 44,726 (68,115) | 28,521 (40,417) | <.001 | No | 8,207 (11,545) | 5,249 (9,532) | <.001 | 37,757 (61,732) | 18,650 (30,852) | <.001 | Anxiolytic use | | | | | | | Yes | 9,645 (12,542) | 6,759 (10,555) | <.001 | 41,463 (64,007) | 23,932 (33,989) | <.001 | No | 7,516 (10,973) | 4,460 (8,937) | <.001 | 36,055 (60,856) | 15,849 (29,053) | <.001 | Aspirin use | | | | | | | Yes | 9,134 (11,978) | 6,605 (10,467) | <.001 | 38,776 (60,824) | 22,564 (32,235) | <.001 | No | 7,645 (11,325) | 4,448 (8,929) | <.001 | 37,667 (63,405) | 16,422 (30,406) | <.001 | Antidepressant use | | | | | | | Yes | 9,530 (12,214) | 7,575 (11,142) | <.001 | 40,833 (62,711) | 25,416 (37,278) | <.001 | No | 8,021 (11,482) | 5,143 (9,483) | <.001 | 37,437 (62,006) | 18,393 (30,605) | <.001 | Nonsteroidal anti-inflammatory drug use | | | | | | | Yes | 8,688 (11,639) | 6,205 (10,322) | <.001 | 41,509 (63,402) | 22,247 (30,768) | <.001 | No | 8,296 (11,672) | 5,131 (9,470) | <.001 | 37,553 (61,919) | 18,136 (31,449) | <.001 | Lipid-lowering drug use | | | | | | | Yes | 8,786 (11,249) | 6,607 (10,125) | <.001 | 34,773 (53,355) | 21,352 (28,326) | <.001 | No | 8,786 (11,889) | 4,682 (9,345) | <.001 | 40,121 (66,987) | 17,763 (32,830) | <.001 | Antihypertensives drug use | | | | | | | Yes | 8,481 (11,736) | 6,374 (10,317) | <.001 | 38,309 (61,979) | 21,918 (31,823) | <.001 | No | 6,916 (10,701) | 2,745 (7,110) | <.001 | 36,890 (64,541) | 11,547 (28,748) | <.001 | Hypoglycemic agent use | | | | | | | Yes | 10,562 (13,088) | 8,131 (11,646) | <.001 | 42,327 (63,140) | 27,313 (35,781) | <.001 | No | 7,912 (11,303) | 4,873 (9,189) | <.001 | 37,359 (61,950) | 17,559 (30,246) | <.001 |
|
|